3 SEHK Stocks That May Be Undervalued In September 2024

As global markets experience a mixed performance, the Hong Kong market has shown resilience with the Hang Seng Index gaining 2.14% recently. Amidst this environment, identifying undervalued stocks can be an effective strategy for investors looking to capitalize on potential growth opportunities.

Top 10 Undervalued Stocks Based On Cash Flows In Hong Kong

Name	Current Price	Fair Value (Est)	Discount (Est)
Bosideng International Holdings (SEHK:3998)	HK$3.85	HK$6.76	43.1%
Zhaojin Mining Industry (SEHK:1818)	HK$12.44	HK$21.36	41.8%
WuXi XDC Cayman (SEHK:2268)	HK$19.64	HK$39.11	49.8%
Pacific Textiles Holdings (SEHK:1382)	HK$1.52	HK$2.85	46.7%
China Renaissance Holdings (SEHK:1911)	HK$7.27	HK$12.30	40.9%
United Company RUSAL International (SEHK:486)	HK$2.35	HK$4.25	44.7%
Vobile Group (SEHK:3738)	HK$1.54	HK$2.63	41.5%
AK Medical Holdings (SEHK:1789)	HK$4.16	HK$8.30	49.9%
DPC Dash (SEHK:1405)	HK$69.95	HK$134.44	48%
Jinke Smart Services Group (SEHK:9666)	HK$8.29	HK$13.99	40.7%

Click here to see the full list of 32 stocks from our Undervalued SEHK Stocks Based On Cash Flows screener.

Here's a peek at a few of the choices from the screener.

Beijing Chunlizhengda Medical Instruments (SEHK:1858)

Overview: Beijing Chunlizhengda Medical Instruments Co., Ltd. is an orthopedic medical device company involved in the research, development, production, and trading of surgical implants and instruments in China, with a market cap of HK$4.10 billion.

Operations: Revenue from the manufacture and trading of surgical implants, instruments, and related products amounted to CN¥1.05 billion.

Estimated Discount To Fair Value: 18.3%

Beijing Chunlizhengda Medical Instruments is trading at HK$6.79, below its estimated fair value of HK$8.31, indicating it may be undervalued based on cash flows. Despite a recent decline in earnings and sales for the first half of 2024, the company’s revenue and earnings are forecast to grow significantly faster than the Hong Kong market over the next three years. The stock also offers good relative value compared to peers and industry benchmarks.

• Upon reviewing our latest growth report, Beijing Chunlizhengda Medical Instruments' projected financial performance appears quite optimistic.
• Click here to discover the nuances of Beijing Chunlizhengda Medical Instruments with our detailed financial health report.

Binjiang Service Group (SEHK:3316)

Overview: Binjiang Service Group Co. Ltd. provides property management and related services in the People’s Republic of China and has a market cap of HK$4.72 billion.

Operations: The company's revenue segments (in millions of CN¥) are property management services, valued at 1.25 billion CN¥, and related services, which amount to 750 million CN¥.

Estimated Discount To Fair Value: 34.1%

Binjiang Service Group is trading at HK$16.94, significantly below its estimated fair value of HK$25.72, highlighting its potential undervaluation based on cash flows. Despite a forecasted revenue growth of 19% per year and earnings growth of 18.9% per year, the stock remains undervalued by over 20%. Recent earnings showed an increase in net income to CNY 265.32 million for the first half of 2024, with ongoing dividend payments enhancing investor confidence.

• Our expertly prepared growth report on Binjiang Service Group implies its future financial outlook may be stronger than recent results.
• Click here and access our complete balance sheet health report to understand the dynamics of Binjiang Service Group.

China Medical System Holdings (SEHK:867)

Overview: China Medical System Holdings Limited is an investment holding company that manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China with a market cap of HK$17.30 billion.

Operations: The company generates CN¥7.01 billion from the marketing, promotion, sales, and manufacturing of pharmaceutical products in the People’s Republic of China.

Estimated Discount To Fair Value: 29.0%

China Medical System Holdings is trading at HK$7.16, significantly below its estimated fair value of HK$10.08, indicating substantial undervaluation based on cash flows. Despite a forecasted revenue growth of 15.2% per year and earnings growth of 21.4% per year, recent results showed a decline in sales to CNY 3.61 billion and net income to CNY 910 million for the first half of 2024, with profit margins dropping from last year’s levels.

• Our growth report here indicates China Medical System Holdings may be poised for an improving outlook.
• Take a closer look at China Medical System Holdings' balance sheet health here in our report.

Where To Now?

• Click here to access our complete index of 32 Undervalued SEHK Stocks Based On Cash Flows.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com